A detailed history of Principal Financial Group Inc transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 16,507 shares of CARA stock, worth $5,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,507
Previous 18,046 8.53%
Holding current value
$5,447
Previous $13,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$0.52 - $1.05 $800 - $1,615
-1,539 Reduced 8.53%
16,507 $15,000
Q4 2023

Feb 07, 2024

SELL
$0.6 - $1.65 $769 - $2,115
-1,282 Reduced 6.63%
18,046 $13,000
Q3 2023

Nov 02, 2023

BUY
$1.67 - $3.33 $2,384 - $4,755
1,428 Added 7.98%
19,328 $32,000
Q2 2023

Aug 07, 2023

SELL
$2.83 - $4.94 $744,210 - $1.3 Million
-262,972 Reduced 93.63%
17,900 $50,000
Q1 2023

May 09, 2023

SELL
$4.89 - $12.27 $18,513 - $46,454
-3,786 Reduced 1.33%
280,872 $1.38 Million
Q4 2022

Feb 09, 2023

SELL
$8.88 - $12.77 $85,478 - $122,924
-9,626 Reduced 3.27%
284,658 $3.06 Million
Q3 2022

Nov 09, 2022

SELL
$8.24 - $12.56 $9,311 - $14,192
-1,130 Reduced 0.38%
294,284 $2.75 Million
Q2 2022

Aug 10, 2022

SELL
$7.45 - $13.84 $525,731 - $976,661
-70,568 Reduced 19.28%
295,414 $2.7 Million
Q1 2022

May 09, 2022

SELL
$9.94 - $12.65 $473,501 - $602,595
-47,636 Reduced 11.52%
365,982 $4.45 Million
Q4 2021

Feb 09, 2022

BUY
$11.99 - $18.14 $726,366 - $1.1 Million
60,581 Added 17.16%
413,618 $5.04 Million
Q3 2021

Nov 09, 2021

SELL
$11.55 - $16.06 $149,179 - $207,430
-12,916 Reduced 3.53%
353,037 $5.45 Million
Q2 2021

Aug 10, 2021

BUY
$12.38 - $29.19 $4.4 Million - $10.4 Million
355,537 Added 3413.37%
365,953 $5.22 Million
Q1 2021

May 10, 2021

SELL
$15.07 - $21.71 $105 - $151
-7 Reduced 0.07%
10,416 $226,000
Q4 2020

Feb 08, 2021

BUY
$12.72 - $16.16 $132,580 - $168,435
10,423 New
10,423 $158,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $17.7M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.